Moxifloxacin in the treatment of community-acquired pneumonia in adults: what''s new?
The article is devoted to the role of respiratory fluoroquinolones in the treatment of community-acquired pneumonia. Respiratory fluoroquinolones are key in the treatment of the disease as they affect virtually all pathogens of community-acquired pneumonia, and have attractive pharmacokinetic and pharmacodynamic profiles. The article tells about the results of several multicenter clinical trials of moxifloxacin and its use as a second-line therapy in tuberculosis of the respiratory tract.